Natural and Induced Human Antibody Response to Cancer

References

• Papac R J. Spontaneous regression of cancer. Cancer Treat Rev 1996; 22: 395–423
   PubMed Web of Science ®Google Scholar
• Cole W H. Spontaneous regression of cancer. The metabolic triumph of the host. Ann NY Acad Sci 1974; 230: 111–141
   PubMed Web of Science ®Google Scholar
• Horn L, Horn H. An immunologic approach to the treatment of cancer. Lancet 1971; 2: 466–469
   PubMed Web of Science ®Google Scholar
• Bolande R P. The spontaneous regression of neuroblastoma: experimental evidence for a natural host immunity. Pathol Annu 1991; 26: 187–199
   PubMedGoogle Scholar
• Darnell R B, De Angelis L M. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341: 21–22
   Google Scholar
• Zaheer W, Friedland M L, Cooper E B. Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy. Cancer Invest 1993; 11: 306–309
   PubMed Web of Science ®Google Scholar
• Winter S F, Sekio Y, Minna J D. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993; 85: 2012–2018
   PubMed Web of Science ®Google Scholar
• Livingston P O, Zhang S, Lloyd K O. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol Immunother 1997; 45: 1–9
   PubMed Web of Science ®Google Scholar
• Livingston P O, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997; 45: 10–19
   PubMed Web of Science ®Google Scholar
• Slinghuff C L, Seigler H F. Immunotherapy for malignant melanoma with a tumor cell vaccine. Ann Plast Surg 1992; 28: 104–107
   PubMed Web of Science ®Google Scholar
• Ahn S S, Irie R F, Weisenberger T H. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response. Surgery 1982; 92: 362–367
   PubMed Web of Science ®Google Scholar
• Chee D O, Gupta R K, Morton D L. Presence of a carcinoma-associated antigen(s) in the spent chemically defined medium of a human colon carcinoma cell line. J Surg Oncol 1980; 13: 45–51
   PubMed Web of Science ®Google Scholar
• Applebaum J, Reynolds S, Knispel J. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst 1998; 90: 146–149
   PubMed Web of Science ®Google Scholar
• Livingston P O, Natoli E J, Calves M J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 2911–2915
   PubMed Web of Science ®Google Scholar
• Livingston P O, Wong G YC, Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036–1044
   PubMed Web of Science ®Google Scholar
• Houghton A N, Taormina M C, Ikeda H. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci USA 1980; 77: 4260–4264
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Schmitt H. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810–11813
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Funikawa K, Fortunato S R. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proc Natl Acad Sci USA 1990; 87: 3333–3337
   PubMed Web of Science ®Google Scholar
• Tai T, Paulson J C, Cahan L D. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci USA 1983; 80: 5392–5396
   PubMed Web of Science ®Google Scholar
• Cahan L D, Irie R F, Singh R. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982; 79: 7629–7633
   PubMed Web of Science ®Google Scholar
• Lloyd K O. Tumor antigens known to be immunogenic in man. Specific Immunotherapy of Cancer with Vaccines, JC Bystryn, S Ferrone, P Livingston. New York, Academy of Sciences, New York 1993
   Google Scholar
• Yagyu T, Monden T, Baba M. A cancer-reactive human monoclonal antibody derived from a colonic cancer patient treated with local immunotherapy. Jpn J Cancer Res 1993; 84: 75–82
   PubMedGoogle Scholar
• Haspel M V, McCabe R P, Pomato N. Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 1985; 45: 3951–3961
   PubMed Web of Science ®Google Scholar
• Borup-Christensen P, Erb K, Ditzel H. Human-human hybridoma producing monoclonal antibodies against colorectal cancer-associated antigens. APMIS 1990; 98: 674–684
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Kato M, Sato S. Characterization of a lung cancer-associated human monoclonal antibody HB4C5. Hum Antib Hybrid 1991; 2: 116–123
   PubMedGoogle Scholar
• Ben-Mahrez K, Sorokine I, Thierry D. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990; 46: 35–38
   PubMed Web of Science ®Google Scholar
• Winter S F, Minna J D, Johnson B E. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168–4174
   PubMed Web of Science ®Google Scholar
• Bodurtha B J, Chee D O, Laucius J F. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res 1975; 35: 189–193
   PubMed Web of Science ®Google Scholar
• Morton D L, Malmgren R A, Holmes E C. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 1968; 64: 233–240
   PubMed Web of Science ®Google Scholar
• Muna N M, Marcus S, Smart C. Detection by immunofluorescence of antibodies specific for human malignant melanoma cells. Cancer 1969; 23: 88–93
   PubMed Web of Science ®Google Scholar
• Nagel G A, Piessens W F, Stilmant M M. Evidence for tumor-specific immunity in human melanoma. Eur J Cancer 1971; 7: 41–47
   PubMed Web of Science ®Google Scholar
• Nairn R C, Nind A P, Guli E P. Anti-tumor immunoreactivity in patients with malignant melanoma. Med J Australia 1972; 1: 397–403
   PubMed Web of Science ®Google Scholar
• Gupta R K, Morton D L. Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanomas. Cancer Res 1975; 35: 58–62
   PubMed Web of Science ®Google Scholar
• Gupta R K, Theofilopoulos A N, Dixon F J. Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol Immunother 1979; 6: 211–221
   Web of Science ®Google Scholar
• Kirkwood J M, Vlock D R. Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res 1984; 44: 4177–4182
   PubMed Web of Science ®Google Scholar
• Vlock D R, Kirkwood J M. Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes. J Clin Invest 1985; 76: 849–854
   PubMed Web of Science ®Google Scholar
• Vlock D R, DerSimonian R, Kirkwood J M. Prognostic role of antibody reactivity to melanoma. J Clin Invest 1986; 77: 1116–1121
   PubMed Web of Science ®Google Scholar
• Vlock D R, Scalise D, Meglin N. Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody. J Clin Invest 1988; 81: 1746–1751
   PubMed Web of Science ®Google Scholar
• Wong J H, Gupta R K, Morton D L. Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma. Arch Surg 1986; 121: 1342–1345
   PubMed Web of Science ®Google Scholar
• Gupta R K, Morton D L. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992; 6: 329–336
   PubMed Web of Science ®Google Scholar
• Wong J H, Xu S H, Skinner K A. Prospective evaluation of the use of antigen-specific immune complexes in predicting the development of recurrent melanoma. Arch Surg 1991; 126: 1450–1454
   PubMed Web of Science ®Google Scholar
• Higuchi M, Gupta R K, Irie R F. Natural humoral immunity in patients with malignant disease. J Clin Lab Immunol 1980; 4: 141–143
   PubMedGoogle Scholar
• Jones P C, Sze L L, Liu P Y. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66: 249–254
   PubMed Web of Science ®Google Scholar
• Gupta R K, Leitch A M, Morton D L. Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients. Cancer Immunol Immunother 1983; 16: 40–47
   PubMed Web of Science ®Google Scholar
• Shiku H, Takahashi T, Oettgen H F. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med 1976; 144: 873–881
   PubMed Web of Science ®Google Scholar
• Shiku H, Takahashi T, Resnick L A. Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristic J Exp Med 1977; 145: 784–789
   Google Scholar
• Carey T E, Takahashi T, Resnick L A. Cell surface antigens of human malignant melanoma: I. Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 1976; 73: 3278–3282
   PubMed Web of Science ®Google Scholar
• Bystryn J C, Henn M, Li J. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 1992; 52: 5948–5953
   PubMed Web of Science ®Google Scholar
• Carey T E, Lloyd K O, Takahashi T. AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization. Proc Natl Acad Sci USA 1979; 76: 2898–2902
   PubMed Web of Science ®Google Scholar
• Real F X, Mattes M J, Houghton A N. Class 1 (unique) tumor antigens of human melanoma: Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med 1984; 160: 1219–1233
   PubMed Web of Science ®Google Scholar
• Vlock D R, Aul D J, Toporowicz A. Purification and partial characterization of a shed 66 kDa melanoma-associated antigen identified by autologous antibody. Biochim Biophys Acta 1991; 1080: 1–10
   PubMed Web of Science ®Google Scholar
• Toporowicz A, Gersten D M, Hearing V J. Cross-reactivity between murine melanoma antigen B700 and a human melanomaassociated antigen (M-66) recognized by autologous antibody: evidence suggesting shared epitopes. Biochim Biophys Acta 1993; 1182: 51–56
   PubMed Web of Science ®Google Scholar
• Kummer U, Staerz U. Concepts of antibody-mediated cancer therapy. Cancer Invest 1993; 11: 174–184
   PubMed Web of Science ®Google Scholar
• Dillman R O. Antibodies and cytotoxic therapy. J Clin Oncol 1994; 12: 1497–1515
   PubMed Web of Science ®Google Scholar
• Jurcic J G, Scheinberg D A, Houghton A N. Monoclonal antibody therapy of cancer. Cancer Chemother Biol Resp Mod 1996; 16: 168–188
   Google Scholar
• Hamilton W B, Helling F, Lloyd K O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993; 53: 566–573
   PubMed Web of Science ®Google Scholar
• Helling F, Livingston P O. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin Mol Chem Neuropathol 1994; 21: 299–309
   PubMedGoogle Scholar
• Ritter G, Boosfeld E, Adluri R. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 1991; 48: 379–385
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Furukawa K, Fortunate S R. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 2416–2420
   PubMed Web of Science ®Google Scholar
• Seigler H F, Wallack M K, Vervaert C E. Melanoma patient antibody responses to melanoma tumor-associated antigen defined by murine monoclonal antibodies. J Biol Resp Mod 1989; 8: 37–52
   PubMedGoogle Scholar
• Hsueh E C, Gupta R, Qi K. K. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997; 3: 364–370
   PubMed Web of Science ®Google Scholar
• Hsueh E C, Famatiga E, Gupta R K. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (Cancer Vax): correlation with survival. Ann Surg Oncol 1998; 5: 595–602
   PubMed Web of Science ®Google Scholar
• Livingston P O, Takeyama H, Pollack M S. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 1983; 31: 567–575
   PubMed Web of Science ®Google Scholar
• Livingston P O, Albino A P, Chung T JC. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 1985; 55: 713–720
   PubMed Web of Science ®Google Scholar
• Livingston P O, Kaelin K, Pinsky C M. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer 1985; 56: 2194–2200
   PubMed Web of Science ®Google Scholar
• Kitamura K, Livingston P O, Fortunato S R. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci US A 1995; 92: 2805–2809
   PubMed Web of Science ®Google Scholar
• Chattopadhyay P, Starkey J, Morrow W J. Murine monoclonal anti-idiolope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc Natl Acad Sci USA 1992; 89: 2684–2688
   PubMed Web of Science ®Google Scholar
• Chattopadhyay P, Sneed D, Rosenberg J. Monoclonal antiidiotypic antibodies to human melanoma-associated proteoglycan antigen: generation and characterization of anti-idiotype antibodies. Cancer Res 1991; 51: 3183–3192
   PubMed Web of Science ®Google Scholar
• Sen G, Chakraborty M, Foon K A. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2 human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody Mel-1. J Immunother 1998; 21: 75–83
   PubMed Web of Science ®Google Scholar
• Baharav E, Merimsky O, Altomonte M. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Melanoma Res 1995; 5: 337–343
   PubMed Web of Science ®Google Scholar
• Lehmann P V, Sercarz E E, Forsthuber T. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993; 14: 203–208
   PubMedGoogle Scholar
• Foon K A, Sen G, Hutchins L. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 1998; 4: 1117–1124
   PubMed Web of Science ®Google Scholar
• Levy R, Miller R A. Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr 1990; 10: 61–68
   PubMedGoogle Scholar
• Hsu F J, Caspar C B, Czerwinski D. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997; 89: 3129–3135
   PubMed Web of Science ®Google Scholar
• Barbuto J AM, Verastegui E L, Hersh E M. The use of transformed T cell lines for clonal expansion of human B cells from peripheral blood, spleen and tumor-infiltrating lymphocytes. Hybridoma 1993; 12: 115–125
   PubMed Web of Science ®Google Scholar
• Punt C JA, Barbuto J AM, Zhang H. Antitumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother 1994; 38: 225–232
   PubMed Web of Science ®Google Scholar
• Barbuto J AM, Grimes W J, Hersh E M. Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction. Cancer Immunol. Immunother 1995; 40: 31–36
   Web of Science ®Google Scholar
• Zhang H, Lake D F, Barbuto J AM. A human monoclonal antimelanoma single-chain Fv antibody derived from tumor-infiltrating lymphocytes. Cancer Res 1995; 55: 3584–3591
   PubMed Web of Science ®Google Scholar
• Cole S PC, Campling B G, Louwman I H. A strategy for the production of human monoclonal antibodies reactive with lung tumor cell lines. Cancer Res 1984; 44: 2750–2753
   PubMed Web of Science ®Google Scholar
• Watson D B, Burns G F, Mackay I R. In vitro growth of B lymphocytes infiltrating human melanoma tissue by transformation with EBV: Evidence for secretion of anti-melanoma antibodies by some transformed cells. J Immunol 1983; 130: 2442–2447
   PubMed Web of Science ®Google Scholar
• Yeilding N M, Gerstner C, Kirkwood J M. . Analysis of two human monoclonal antibodies against melanoma. Int J Cancer 1992; 52: 967–973
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9: 709–716
   PubMed Web of Science ®Google Scholar
• Tureci O, U S, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997; 342–349
   PubMedGoogle Scholar
• Tureci O, Schmitt H, Fadle N. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem 1997; 272: 6416–6422
   PubMed Web of Science ®Google Scholar
• Chen Y T, Scanlan M J, Sahin U. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1914–1918; 94, 1997
   Google Scholar
• Stockert E, Jager E, Chen Y T. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 1349–1354
   PubMed Web of Science ®Google Scholar
• Old L J. Cancer immunology: the search for specificity. G.H.A. Clowes Memorial Lecture. Cancer Res 1981; 41: 361–375
   PubMed Web of Science ®Google Scholar